-
公开(公告)号:US20090181991A1
公开(公告)日:2009-07-16
申请号:US12090844
申请日:2006-11-03
申请人: Qiong Zhang , Nathanael S. Gray , Yi Liu , Qiang Ding , Tetsuo Uno
发明人: Qiong Zhang , Nathanael S. Gray , Yi Liu , Qiang Ding , Tetsuo Uno
IPC分类号: A61K31/505 , C07D239/42 , C07D213/74 , A61K31/44
CPC分类号: C07D239/48 , C07D213/74 , C07D239/42 , C07D239/47 , C07D239/52
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Lck, IR, IGF-1R, JNK1α, Flt3, Fes, EFGR (Her-1, erbB-1), cSRC, CDK1/cyclinB, c-RAF, BTK, Bmx, Axl, Aurora-A, Abl, BCR-Abl, TrkB, Tie2, Syk, SGK, SAPK2a, Rsk1 and Met kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Lck,IR,IGF异常活化的疾病或病症 -1R,JNK1alpha,Flt3,Fes,EFGR(Her-1,erbB-1),cSRC,CDK1 / cyclinB,c-RAF,BTK,Bmx,Ax1,Aurora-A,Abl,BCR-Abl,TrkB,Tie2, Syk,SGK,SAPK2a,Rsk1和Met激酶。
-
公开(公告)号:US07449582B2
公开(公告)日:2008-11-11
申请号:US10961646
申请日:2004-10-08
申请人: Qiang Ding , Yongping Xie , Nathanael S. Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
发明人: Qiang Ding , Yongping Xie , Nathanael S. Gray , Shuli You , Greg Chopiuk , Jiqing Jiang , Yi Liu , Ruo Steensma , Xing Wang , Taebo Sim
IPC分类号: C07D215/38 , C07D471/02 , C07D251/38
CPC分类号: C07D471/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,CSK,JNK1,JNK2,PDGF-R,p38,p70S6K,TGFbeta,SRC,EGFR,c-Kit,trkB,FGFR3,Fes,Lck,Syk,RAF,MKK4,MKK6和SAPK2β激酶。
-
公开(公告)号:US20080108616A1
公开(公告)日:2008-05-08
申请号:US11970278
申请日:2008-01-07
申请人: Qiang Ding , Nathanael Gray , Bing Li , Yi Liu , Tetsuo Uno
发明人: Qiang Ding , Nathanael Gray , Bing Li , Yi Liu , Tetsuo Uno
IPC分类号: C07D487/04 , A61K31/5377 , A61K31/496 , C07D413/14 , C07D403/14 , A61K31/519 , A61P35/00
CPC分类号: C07D487/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2α and SAPK2β kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,CSK,TrkB,FGFR3,Fes,Lck,B-RAF,C-RAF,MKK6,SAPK2alpha和SAPK2β激酶。
-
公开(公告)号:US07642255B2
公开(公告)日:2010-01-05
申请号:US12099708
申请日:2008-04-08
申请人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
发明人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
IPC分类号: C07D413/14 , C07D471/04 , C07D487/04 , A61K31/535 , A61K31/497 , A61K31/519 , C07D251/12 , A61K31/53 , A61P35/00
CPC分类号: C07D487/04 , C07D471/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,c-Raf,Csk,Fes,FGFR,Flt3,Ikk,IR,JNK,Lck,Mkk,PKC,PKD,Rsk,SAPK,Syk,Trk,BTK,Src,EGFR,IGF,Mek,Ros和Tie2 激酶。
-
公开(公告)号:US20090137804A1
公开(公告)日:2009-05-28
申请号:US11570983
申请日:2005-06-23
申请人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Taebo Sim , Tetsuo Uno , Guobao Zhang , Carole Pissot Soldermann , Werner Breitenstein , Guido Bold , Giorgio Caravatti , Pascal Furet , Vito Guagnano , Marc Lang , Paul W. Manley , Joseph Schoepfer , Carsten Spanka
发明人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Taebo Sim , Tetsuo Uno , Guobao Zhang , Carole Pissot Soldermann , Werner Breitenstein , Guido Bold , Giorgio Caravatti , Pascal Furet , Vito Guagnano , Marc Lang , Paul W. Manley , Joseph Schoepfer , Carsten Spanka
IPC分类号: A61K31/50 , C07D239/12 , A61P35/00
CPC分类号: C07D239/48 , C07D251/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
摘要翻译: 本发明涉及式(I)化合物,其中取代基X1,R1,R2,R3和R4具有本发明说明书中阐述和解释的含义,制备这些化合物的方法,含有它们的药物组合物 ,其任选与一种或多种其它药学活性化合物组合用于治疗对蛋白激酶活性的抑制作出反应的疾病的用途,以及治疗这种疾病的方法。
-
公开(公告)号:US07338957B2
公开(公告)日:2008-03-04
申请号:US10927992
申请日:2004-08-26
申请人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Tetsuo Uno
发明人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Tetsuo Uno
IPC分类号: C07D487/04 , A61K31/519 , A61P35/00
CPC分类号: C07D487/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2α and SAPK2β kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,CSK,TrkB,FGFR3,Fes,Lck,B-RAF,C-RAF,MKK6,SAPK2alpha和SAPK2β激酶。
-
公开(公告)号:US08552002B2
公开(公告)日:2013-10-08
申请号:US11570983
申请日:2005-06-23
申请人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Taebo Sim , Tetsuo Uno , Guobao Zhang , Carole Pissot Soldermann , Werner Breitenstein , Guido Bold , Giorgio Caravatti , Pascal Furet , Vito Guagnano , Marc Lang , Paul William Manley , Joseph Schoepfer , Carsten Spanka
发明人: Qiang Ding , Nathanael Schiander Gray , Bing Li , Yi Liu , Taebo Sim , Tetsuo Uno , Guobao Zhang , Carole Pissot Soldermann , Werner Breitenstein , Guido Bold , Giorgio Caravatti , Pascal Furet , Vito Guagnano , Marc Lang , Paul William Manley , Joseph Schoepfer , Carsten Spanka
IPC分类号: A01N43/54 , C07D239/02
CPC分类号: C07D239/48 , C07D251/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12
摘要: The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.
摘要翻译: 本发明涉及式(I)化合物,其中取代基X1,R1,R2,R3和R4具有本发明说明书中阐述和解释的含义,制备这些化合物的方法,含有它们的药物组合物 ,其任选与一种或多种其它药学活性化合物组合用于治疗对蛋白激酶活性的抑制作出反应的疾病的用途,以及治疗这种疾病的方法。
-
公开(公告)号:US20080221098A1
公开(公告)日:2008-09-11
申请号:US12099708
申请日:2008-04-08
申请人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
发明人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Schiander Gray , Shuli You
IPC分类号: A61K31/5377 , C07D487/04 , A61K31/519 , A61K31/496
CPC分类号: C07D487/04 , C07D471/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,c-Raf,Csk,Fes,FGFR,Flt3,Ikk,IR,JNK,Lck,Mkk,PKC,PKD,Rsk,SAPK,Syk,Trk,BTK,Src,EGFR,IGF,Mek,Ros和Tie2 激酶。
-
公开(公告)号:US07371750B2
公开(公告)日:2008-05-13
申请号:US10909227
申请日:2004-07-29
申请人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Guobao Zhang , Yi Liu , Xia Wang , Tetsuo Uno , Bing Li , Lintong Li , Nathanael Schiander Gray , Shuli You
发明人: Taebo Sim , Hyun Soo Lee , Pingda Ren , Qiang Ding , Guobao Zhang , Yi Liu , Xia Wang , Tetsuo Uno , Bing Li , Lintong Li , Nathanael Schiander Gray , Shuli You
IPC分类号: A61K31/5355 , A61K31/53 , A61K31/497 , A61K31/513 , C07D413/12 , C07D253/065 , C07D487/04 , C07D413/14 , A61P35/00 , C07D471/04
CPC分类号: C07D487/04 , C07D471/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,c-Raf,Csk,Fes,FGFR,Flt3,Ikk,IR,JNK,Lck,Mkk,PKC,PKD,Rsk,SAPK,Syk,Trk,BTK,Src,EGFR,IGF,Mek,Ros和Tie2 激酶。
-
公开(公告)号:US20050222177A1
公开(公告)日:2005-10-06
申请号:US10909227
申请日:2004-07-29
申请人: Taebo Sim , Hyun Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Gray , Shuli You
发明人: Taebo Sim , Hyun Lee , Pingda Ren , Qiang Ding , Yi Liu , Bing Li , Lintong Li , Xia Wang , Tetsuo Uno , Guobao Zhang , Nathanael Gray , Shuli You
IPC分类号: A61K20060101 , A61K31/5025 , A61K31/519 , C07D471/04 , C07D487/02 , C07D487/04
CPC分类号: C07D487/04 , C07D471/04
摘要: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
摘要翻译: 本发明提供了一类新颖的化合物,包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法,特别是涉及Abl,BCR-Abl异常活化的疾病或病症 ,Bmx,c-Raf,Csk,Fes,FGFR,Flt3,Ikk,IR,JNK,Lck,Mkk,PKC,PKD,Rsk,SAPK,Syk,Trk,BTK,Src,EGFR,IGF,Mek,Ros和Tie2 激酶。
-
-
-
-
-
-
-
-
-